LumiraDx, in collaboration with AstraZeneca and Everton in the Community, is launching England's first community-based heart and lung screening hub, set to begin operations in November.
The hub, run by Everton Football Club's charity, aims to provide early diagnosis and treatment for chronic breathlessness and related conditions using innovative diagnostics and artificial intelligence.
The LumiraDx NT-proBNP test, performed with a simple fingerstick sample, will be a key tool in this endeavour, providing rapid results within 12 minutes. The hub will address conditions like heart failure, chronic obstructive pulmonary disease (COPD), and offer lifestyle guidance.
LumiraDx's initiative focuses on improving patient outcomes and access to vital diagnostics within the community. This effort will also involve collaboration with medical technology providers and the Liverpool University Hospitals NHS Foundation Trust.
Click here to read the original news story.